CHUC · XBRL financial data

Charlie's Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CHUC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	17	—	26	16	—	—
Cost of goods and services sold	7	—	—	—	5	15
Gross profit	—	—	—	—	3	6
Research and development	3	0	1	0	—	—
General and administrative	11	9	8	7	6	6
Total operating expenses	23	21	28	18	12	8
Operating income (loss)	(7)	1	(2)	(2)	(3)	(2)
Interest expense	0	0	0	0	1	1
Other income (expense)	(0)	5	0	0	(1)	—
Income tax expense (benefit)	0	0	(0)	0	0	0
Net income (loss)	(7)	5	(2)	(2)	(4)	4
Earnings per share, basic USD per share	(0.04)	0.02	(0.01)	(0.01)	(0.02)	0.02
Earnings per share, diluted USD per share	(0.04)	0.01	(0.01)	(0.01)	(0.02)	0.02
Weighted average shares, basic millions of shares	190	204	212	216	235	257
Weighted average shares, diluted millions of shares	190	238	212	216	235	279

† Share count changed about 1/91 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CHUC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1	1	0	0	0	1
Accounts receivable	1	1	1	0	0	0
Inventory	2	5	4	4	3	7
Prepaid and other current assets	0	1	1	1	0	2
Total current assets	5	8	6	5	4	11
Property and equipment, net	1	0	0	0	0	0
Right-of-use asset	1	1	1	0	0	1
Total assets	7	9	7	6	4	12
Accounts payable	1	2	1	1	2	3
Total current liabilities	11	6	5	5	6	8
Lease liability, non-current	1	0	0	0	0	0
Total liabilities	13	6	5	6	6	8
Accumulated deficit	(10)	(5)	(6)	(9)	(13)	(8)
Total stockholders' equity	(6)	3	2	(0)	(2)	3
Total liabilities and equity	7	9	7	6	4	12
Common shares outstanding (cover page) millions of shares	19,638	217	224	229	257	274

† Share count changed about 1/91 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CHUC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(7)	5	(2)	(2)	(4)	4
Stock-based compensation	3	1	0	0	0	0
Depreciation and amortization	—	—	—	—	0	0
Net cash from operating activities	(3)	(1)	(2)	(1)	(2)	(6)
Purchases of property and equipment	0	0	0	0	0	0
Net cash from investing activities	(0)	(0)	(0)	0	0	7
Proceeds from issuing common stock	0	—	—	0	2	0
Proceeds from issuing equity	0	3	0	—	—	—
Dividends paid	0	1	0	—	—	—
Net cash from financing activities	2	1	1	1	1	(1)
Net change in cash	(1)	(1)	(1)	0	(0)	1

† Share count changed about 1/91 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Charlie's Holdings	0.5	not reported	(0.4)*	280.6M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Cognition Therapeutics	34	not reported	(3.1)*	95.1M	11.1 quarters	Q2 FY26 10-QJun 30, 2026
Ernexa Therapeutics	5	not reported	(4.2)*	1.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
IGC Pharma	0.3	0.3	(1.4)*	103.4M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Marker Therapeutics	11	not reported	(3.7)*	16.7M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Relmada Therapeutics	11	not reported	(9.6)*	106.7M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
CEL-SCI	6.5	not reported	(4)*	17.6M	1.6 quarters	Q3 FY26 10-QJun 30, 2026
Lipocine	5	0.2	(3)*	8.2M	7.7 quarters	Q2 FY26 10-QJun 30, 2026
Evoke Pharma	12	4.3	(0.5)*	1.7M	22.2 quarters	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.